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Abstract 
 
Ferroptosis is a form of regulated cell death that is dependent on iron and reactive oxygen 
species (ROS) and is characterized by lipid peroxidation. It is morphologically and biochemically 
distinct and disparate from other processes of cell death. As ferroptosis is induced by inhibition 
of cysteine uptake or inactivation of the lipid repair enzyme glutathione peroxidase 4 (GPX4), 
the process is favoured by chemical or mutational inhibition of the cystine/glutamate antiporter 
and culminates in the accumulation of reactive oxygen species (ROS) in the form of lipid 
hydroperoxides. Excessive lipid peroxidation leads to death by ferroptosis and the phenotype is 
accentuated respectively by the repletion and depletion of iron and glutathione in cells. 
Furthermore, oxidized phosphatidylethanolamines (PE) harbouring arachidonoyl (AA) and 
adrenoyl moieties (AdA) have been shown as proximate executioners of ferroptosis. Induction 
of ferroptosis due to cysteine depletion leads to the degradation of ferritin, (ferritinophagy) 
which releases iron via NCOA4-mediated autophagy pathway. Evidence of the manifestation of 
ferroptosis in vivo in iron overload mice mutants is emerging. Thus, a concerted synchronization 
of iron-availability, ROS generation, glutamate excess and cysteine deficit leads to ferroptosis. A 
number of questions on the molecular mechanisms of some features and ferroptosis are 
highlighted as subjects for future investigations. 
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Regulated or programmed cell death essentially maintains homeostasis during physiological 
processes such as proliferation, growth, development and immunity. Dysregulation, 
disequilibrium and imbalance in cell death are associated with various disorders including 
different types of cancer. Consequently, apart from classical apoptosis, other forms of 
regulated death have been characterized as necroptosis, pyroptosis, autophagy, parthanatos, 
and lately ferroptosis, as discrete and disparate phenomena [1;2]. Table 1 shows the features of 
some forms of cell death processes. Ferroptosis, as the name implies, suggests the involvement 
of iron as a distinguishing feature of this form of cell death [3]. It has subsequently been 
characterized as a non-apoptotic peroxidation-induced cell death contingent upon the 
availability of iron and reactive oxygen species (ROS) [3;4]. Cell death manifestation of this 
process occurs without the involvement of apoptotic effectors such as caspases, BAX, and BAK. 
Moreover, it is independent of the inducer of necrosis, receptor-interacting protein kinase 3 
(RIPK1/RIPK3) [3].. Consequently, morphological features of ferroptosis are intact cell 
membrane devoid of blebbing, normal-sized nucleus free of chromatin condensation and dense 
miniature mitochondria with vestigial cristae [5]. Biochemically, ferroptosis is characterized by 
the accumulation of ROS from iron metabolism, NADPH oxidase activity and lipid peroxidation 
products. It is induced by perturbations in signaling and membrane transport processes such as 
mitogen-activated protein kinases (MAPK), activation of mitochondrial voltage-dependent 
anion channels (VDAC) and inhibition of a specific light-chain subunit of the cystine/glutamate 
antiporter (SLC7A11, or system Xc-) particularly in cell culture. However, SLC7A11 knockout is 
not lethal due to the presence of residual cysteine in the plasma and tissue of mice [6]. 
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Metabolically, glutaminolysis that is enhanced by the abundance of L-glutamine and transferrin, 
particularly when cysteine is deficient, promotes ferroptosis [7]. Furthermore, transcriptional 
inhibition of cystine-glutamate antiporter, SLC7A11 by mutant p53 enhances ferroptosis [8]. 
However, some mutant forms of p53 may not suppress SLC7A11 expression. For example, a p53 
that harboured mutations in the N-terminal domain of the gene was not functional in the 
down-regulation of SLC7A11 [41].  Erastin and RAS-selective lethal small molecule 3 (RSL) were 
identified as compounds that were selectively lethal in a non-apoptotic manner to oncogenic 
Ras mutant cells before the concept of ferroptosis emerged [2]. Sorafenib and sulfasalazine also 
inhibit SLC7A11. Other inducers of ferroptosis, include buthionine sulfoximine, as well as 
pharmacological drugs such as, acetaminophen, lanperisone, and artesunate [2]. 
Ferroptosis has thus emerged recently as a paradigm characterized by a multiplicity of inducers 
and inhibitors that initiate increased accumulation of ROS and lipid peroxides to cause a 
discrete but distinct non-apoptotic cell death phenotype [9]. Conditional knockout of the key 
regulator GPX4 has revealed the association of ferroptosis to various disorders including cancer, 
neurodegenerative diseases, acute renal failure amongst others [4;10-14]. Although there are 
several reviews on ferroptosis to date, the current overview is an account that explores the 
experimentation strategies that led to the identification of the salient features of the 
mechanism of the cell death process. 
 
Features of ferroptosis 
Ferroptosis is initiated by events that are yet to be defined in a canonical signally pathway 
chronologically. The following are features of ferroptosis: (a) generation of reactive oxygen 
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species (b) depletion of GPX4 in cells (c) accumulation of lipid hydroperoxides and the (d) 
availability of iron. 
(a) Reactive oxygen species (ROS) and ferroptosis 
ROS are partially reduced oxygen-containing molecules, including superoxide (O2•–), peroxides 
(H2O2 and ROOH) and free radicals (HO• and RO•). Mitochondria generate significant amounts 
of ROS from normal metabolism and energy production in the electron transport chain (Figure 
1). ROS are also endogenously generated from xanthine oxidase in the hydroxylation of 
hypoxanthine via xanthine to uric acid, cytochrome P450 catalytic reactions and by 
microsomes, NADPH oxidase, cyclooxygenases, uncoupled nitric oxide synthase (NOS), 
lipoxygenase and by peroxisomes in the oxidation of fatty acids particularly in the liver. 
Moreover, ROS are generated by activated neutrophils, eosinophils and macrophages during 
defence against infection. ROS are important as secondary messengers in intracellular signaling, 
defense against infection and in apoptosis of cancer cells [15]. Excess ROS are detoxified by 
antioxidants (enzymatic and non-enzymatic) and enzymes including superoxide dismutase (Cu, 
Zn-SOD, Mn-SOD), glutathione peroxidase (GPX) and catalase. Imbalance in the rate of ROS 
generation and detoxification leads to oxidative stress and consequent free radicals that can 
damage DNA, proteins and lipids. Redox-active metals, in particular Fe, could contribute to the 
ROS pool in the cell through Fenton reaction in which Fe catalyzes the breakdown of H2O2 to 
yield hydroxyl radicals (Figure 1). Superoxide radical eventually reduces Fe(III) to produce Fe(II) 
and O2 (Haber-Weiss reaction). Under normal physiological conditions, redox-active Fe(II) in the 
form of the labile iron pool (LIP) is maintained at low concentrations of about 0.2–0.5 µM to 
sustain metabolic needs [16] while excess is sequestered in proteins, including ferritin, to avert 
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toxic repercussions.  However, under conditions of oxidative stress, high levels of superoxide 
could induce Fe(II) release from iron compounds including [4Fe–4S] cluster, heme or ferritin. In 
ferroptosis, inactivation of cystine-glutamate antiporter, (SLC7A11) and glutathione depletion 
cause iron-dependent accumulation of ROS [17].  Moreover, generation of ROS, independent of 
iron could arise from glucose and glutamine metabolism that diminishes glutathione and GPX4 
levels [3;18]. Although a vital hallmark of ferroptosis is the involvement of ROS in peroxidation, 
the identification of other effectors and molecular signaling events that lead to cell death by 
ferroptosis are yet to be characterized.  
(b) Depletion of GPX4 and ferroptosis 
GPX4, an antioxidant enzyme that neutralizes lipid peroxides and protects membrane fluidity. 
GPX4 uses glutathione as a cofactor to catalyze the reduction of lipid peroxides and protects 
cells and membranes against peroxidation. Oxidized glutathione disulfide (GSSG) is 
subsequently reduced by glutathione reductase and NADPH/H+ to recirculate reduced 
glutathione (GSH). The catalytic site of this reaction is at the selenocysteine residue of GPX4 
and the ligand binding of the electrophilic Ras-selective lethal small molecule (RSL3) to the 
nucleophile moiety of the selenocysteine on the active site of GPX4 has been demonstrated 
[19]. RSL3 therefore directly inactivates or inhibits GPX4 activity and induce ferroptosis. 
Inhibition of GPX4 initiates uncontrolled polyunsaturated fatty acid (PUFA) oxidation and fatty 
acid radical generation thereby causing ferroptotic cell death. Intracellular levels of glutathione 
(GSH), a cofactor of GPX4, are also influenced by the function of the system Xc- SLC7A11 
cystine-glutamate antiporter [11]. Erastin, sulfasalazine, sorafenib or glutamate can inhibit the 
transporter and induce ferroptosis.  
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It seems apparent that ferroptosis is triggered or induced mainly by reduced detoxification of 
lipid peroxides by the enzymatic activity of glutathione peroxidase 4 (GPX4) [11] or loss of this 
capacity. Moreover, peroxidation of PUFAs was shown to be the primary driver of ferroptosis in 
these studies. Oxidation of PUFAs by lipoxygenases leads to the accumulation of peroxides that 
may contribute to the generation of lipid peroxide breakdown products. While PUFAs including 
linoleic and arachidonic acids stimulated cells to RSL3–induced ferroptosis, oleic acid, a 
monounsaturated fatty acid (MUFA) had the contrasting effect of inhibition [18][19]. It 
presumably exerts a neutralizing or protective effect against ferroptosis. 
Quite recently, Doll et al [9] reported that acyl-CoA synthetase long-chain family member 4 
(ACSL4) drives ferroptosis via the accumulation of oxidized cellular membrane phospholipids. 
Subsequently, Kagan et al [20;21] identified oxidized phosphatidylethanolamines (PE) as the 
lethal lipid species produced by ACSL4 as inducers of ferroptosis. Doll et al [9] using CRISPR 
technology demonstrated that by knocking down the ACSL4 gene, lipid peroxides production 
and ferroptosis were inhibited in cells. A reversal of this observation was effected by transgenic 
overexpression of ACSL4 in cells in which GPX4 functionality was selectively inhibited to prevent 
confounding effect. Moreover, in vivo corroboration of this evidence was achieved by inhibiting 
ACSL4 with thiazolidinedione in a conditional knockout model of Gpx4 model. Furthermore, the 
revelation of the identity of PE as oxidized species driving ferroptosis was compelling, even 
though complex. Oxidized phospholipids that were produced during ferroptosis were identified 
by genetic, bioinformatics and LC-MS/MS analysis of extracts of RSL-3 sensitive cultured cells 
[22]. The lipid species specific to the induction of ferroptosis were stringently identified in vitro 
and in vivo in GPX4 models in only one class of phosphatidylethanolamines (PE) phospholipids. 
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PEs that harbour two fatty acyls, arachidonoyl (AA) and adrenoyl (AdA) activated by ACSL4 were 
shown to be death signals of ferroptosis particularly in the mitochondria. Gene knockout and 
pharmacological inhibition of ACSL4 attenuated the esterification of arachidonoyl (AA) or 
adrenoyl (AdA) into phosphatidylethanolamines (PE). Finally, the lethal species of double and 
triple-oxygenated (15-hydroperoxy)-diacylated PE peroxides are generated by 15-lipoxygenase 
(LOX). In essence, Acyl-CoA synthetase long-chain family member 4 (ACSL4) catalyzes the 
ligation of an arachidonoyl (AA) or adrenoyl (AdA) to produce AA or AdA acyl Co-A derivatives. 
These are then esterifed into phosphatidylethanolamines (AA-PE and AdA-PE) by 
lysophosphatidylcholine acyltransferase 3 (LPCTA3). Subsequently, AA-PE and AdA-PE, are 
oxidised by 15-lipoxygenase (15-LOX) to generate lipid hydroperoxides, the proximate 
executors of ferroptosis (Figure 2). Lipid hydroperoxides are reduced by GPX4 to inhibit 
ferroptosis. While the GPX4, an antioxidant enzyme neutralizes lipid peroxides, the antioxidant 
vitamin E (α-tocopherol) and α-tocotrienol were shown to regulate ferroptosis via LOX 
suppression [20]. Vitamin E inhibits LOX by also competing at the substrate binding site in 
addition to its ability to scavenge hydroxyl group radicals. Electron spin resonance (ESR) 
spectroscopy and LC-MS were employed to delineate the mechanism by which vitamin E 
inhibits LOX activity via competition with the substrate at the binding site of the enzyme. 
Esterified analogs of vitamin E, α-tocopherol succinate (TS) or α-tocopherol phosphate (TP) 
though unable to generate tocopheroxyl radicals, suppressed LOX activity nevertheless by 
competing for PUFA substrate binding site (the corking mechanism). Vitamin E has been shown 
to protect cells against ferroptotic death in vitro [14;23;24] and in vivo in Gpx4-/- knockout mice 
[41]. Tissue specific expression of 15-LOX and possibly vitamin E status underline disparate 
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organs and disorders that are associated with ferroptosis. Other inhibitors of ferroptosis include 
Liproxstatin-1, Ferostatin -1, ebselen, and Coenzyme Q.  Furthermore, susceptibility and 
sensitivity to ferroptosis inducers vary with different cell types [25]. Some lymphoma cells have 
deficiencies in sulphur transfer pathways and rely on extracellular sources of cysteine and 
cystine. For example, sulfasalazine-induced ferroptosis was inhibited in Nb2 lymphoma cells 
when co-cultured with cysteine secreting fibroblasts or when supplemented with 2-
mercaptoethanol. Moreover, hepatoma carcinoma cells, in response to sorafenib-induced 
ferroptosis exhibited elevation of NAD(P)H Quinone Dehydrogenase 1  (NQO), HO-1 and FTH1 
mRNA levels [26] possibly to attenuate the effects of ROS. In essence, GPX4 inhibition, GSH 
depletion, or increased lipoxygenase activity enhances PUFA accumulation and fatty acid 
radicals including malondialdehyde and 4-hydroxynonenal which induce ferroptosis to cause 
cell death in pathological disorders such as Huntington’s disease, acute kidney disease, B cell 
lymphoma, periventricular leukomalacia, and cancers [6]. 
Iron and ferroptosis  
The involvement of iron from the onset in ferroptosis was revealed when the iron chelator, 
deferoxamine (DFO), abrogated erastin-induced lethality [27]. Evidence from Dixon et al., [3] 
revealed that iron regulatory protein 2 (IRP2) controls cellular iron levels to up-regulate erastin-
induced ferroptosis. IRP2 binds to iron-responsive elements (IREs) which are stem-loop 
structures located in the 5'-UTR of ferritin and ferroportin to repress mRNA translation and in 
the 3'-UTR of transferrin receptor 1 and DMT1 leading to the inhibition of the ubiquitination of 
their mRNA. ALAS2, ACO2 and EPAS1 mRNAs amongst others are regulated by IREs.  
Consequently, shRNA knockdown of transferrin receptor reduced erastin-induced cytotoxicity. 
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In contrast, a knockdown of FBXL5, the E3 ubiquitin ligase that mediates IRP2 ubiquitination, 
promoted erastin-induced cell death [3]. Iron chelation could, however, target any of the 
diverse iron-containing or dependent proteins in cells. Incidentally, some of the proteins are 
iron-containing lipoxygenase and also NADPH oxidase, xanthine oxidase, cytochrome P450 
amongst others. Interestingly, NADPH oxidase (NOX1) function, possibly, in the metabolism of 
Fe/heme binding proteins, is up-regulated in oncogenic RAS mutant cells [28]. The essentiality 
of iron in ferroptosis was confirmed further when transferrin, as holotransferrin, was reported 
to be vital for the induction of ferroptosis [29]. The study employed gene silencing, size 
exclusion fractionation and mass spectrometry to demonstrate that transferrin and glutamine 
are essential for ferroptosis when induced by amino acids or in particular during cystine 
deficiency . This scenario seems optimal for the induction of ferroptosis because reduced 
cystine, lower glutathione or antioxidant level and iron-loaded transferrin are ideal substrates 
and conditions for the generation of ROS in cell culture. The Tf-TfR1 axis and IRE-IRP2 regulation 
might be the link to IRP2 involvement in the initiation of ferroptosis in HT-1080 cells [27]. 
Moreover, TfR1 recycling was shown to be inhibited by heat shock protein B1 (HSPB1) with the 
consequent effect of decreased intracellular iron concentration [30;31]. On the contrary, 
however, inactivation of HSPB1 favored iron accumulation and erastin-induced ferroptosis [32]. 
The compelling evidence is that while iron elevation promotes ferroptosis, the process is 
inhibited by iron chelation [3]. Poignantly, L-glutamate has earlier been shown to inhibit cystine 
transport [33]  and cause cell death in neuronal cells. Moreover, oxidative glutamate-induced 
toxicity in neurons is also abrogated by iron chelation [34] through inhibiting HIF proly 
hydroxylase 1, a 2-oxoglutarate and oxygen-dependent dioxygenase [28]. The authors [35] 
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proposed that iron chelators possibly abrogated ferroptosis by further inhibiting iron-
dependent HIF prolyl hydroxylase. Of note, however, is that IRP2 lacks aconitase activity and 
does not sense iron directly [36]; rather the iron/oxygen sensor, akin to HIF prolyl hydroxylase, 
is FBXL5 ubiquitin ligase that modulates IRP2 degradation. Interestingly, mice with targeted 
ablation of the IRP-2 gene have been reported to have increased levels of iron and ferritin in 
the white matter of the brain before the onset of neurodegeneration [37]. Unlike IRP1, 
neurodegeneration disorders typify the phenotype of IRP2 knockout mice [38]. The role of iron, 
in modulating diverse ferroptosis-inducing compounds and signaling pathways of ferroptosis, 
remain to be elucidated. How does iron modulate the upstream or downstream regulators of 
ferroptosis in the signaling pathway?  
Other features of ferroptosis 
PHKG2, and p53 
What is both intriguing and fascinating is the role of phosphorylase kinase G2 (PHKG2), an 
enzyme that induces the release of glucose-1-phosphate from glycogen, in ferroptosis. 
Phosphorylase kinase gamma2 is the liver and testicular isoform of PHK while PHKG1 is found 
mainly in the muscle. Mutations in the PHKG2 are associated with glycogen storage disease, 
liver cirrhosis and complications in type 1 diabetes in humans [39;40]. 
Silencing PHKG2 in cells was shown to decrease iron availability which inhibited lipid oxidation 
upon erastin treatment [19]. Thus far, PHKG2 has been suggested, tentatively, to modulate 
erastin sensitivity by its iron regulating function [19]. In essence, modulation of ferroptosis is 
regulated through PHKG2-induced iron availability. However, the manner by which PHKG2 
regulates cytosolic iron levels to influence ferroptosis is still subject to further investigation. 
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One hypothesis is that this might be due to the link between PHKG2 and the recently reported 
non-canonical function of p53. Oncogenetic tumour-suppressive functions of p53 include cell 
cycle arrest, apoptosis, senescence and the newly identified activation of ferroptosis [41;42]. 
The latter is attributed to its inhibitory transcriptional regulation of cystine, cationic amino-acid 
transporter, member 11 (SLC7A11), causing reduced cellular cysteine levels, reduced GSH and 
induction of ferroptosis. In essence, inactivation of acetylation-defective p53 mutant inhibits 
transcription of SLC7A11, hence promoting ROS that facilitates ferroptosis and cell death in 
cancers cells [41]. Furthermore, glutaminase 2 (GLS2), a p53-regulated glutaminase was 
implicated in a glutaminolysis-ferroptosis nexus [7]. Quite remarkably, Jennis et al [43] 
identified a p53 variant that exhibited impaired ability to suppress SLC7A11 or transactivate 
GLS2 as incapable of ferroptosis induction. Consequently, two disparate phenotypic traits 
validated unequivocally the prime function of p53 in ferroptosis. The molecular mechanism by 
which p53 regulates ferroptosis was recently revealed [44] in a report that demonstrated that 
spermidine/spermine N1-acetyltransferase 1 (SAT1), a direct p53 target gene, enhances the 
levels of lipid oxygenase, arachidonate 15-lipoxygenase (ALOX15), an iron-binding enzyme that 
oxidizes polyunsaturated fatty acids (discussed above).  Moreover, levels of SAT1 were found to 
be low in tumour samples and its knockdown significantly inhibited p53-induced ferroptosis. 
Thus, SAT1, in synchrony or (possibly in synergy) with ROS promotes lipid peroxidation that 
leads to ferroptosis. Yet, repression of p53 expression by iron, however, suppresses its 
canonical oncogenic cell death functions [45]. Consequently, a gain of function due to mutation 
and a loss of expression of a protein (p53) lead to contrasting phenotypic effects in different 
variants of the gene.  
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Ferritinophagy 
Ferritinophagy is the autophagic degradation of the iron-storage ferritin protein that maintains 
homeostasis during iron depletion. The pathway is mediated, during low iron levels by nuclear 
receptor co-activator 4 (NCOA4), an autophagy cargo receptor that binds ferritin heavy chain 1 
(FTH1) in autophagosome and it is delivered into the lysosome for degradation to release iron 
for systemic physiological requirements. However, when iron levels in cells are high, NCOA4 
selectively binds to HERC2 (HECT and RLD domain containing E3 ubiquitin protein ligase 2) to 
initiate its proteosomal degradation and ubiquitination [46;47]. Initiation of ferroptosis was 
shown to activate ferritinophagy [48] in a process whereby ferritin catabolism increases the 
labile iron pool (LIP) which promotes ROS accumulation that drives ferroptosis. Gao et al [48] 
employed inhibitors of autophagy and NCOA4 gene knockdown to show that ferroptosis is an 
autophagic cell death process. Inhibition of NCOA4 repressed ferritin degradation and 
suppressed ferroptosis, while its overexpression had the opposite effects [48] . Induction of 
ferroptosis by erastin, independent of transferrin internalization, was shown [19] to cause a 
time-dependent increase of LIP, a process blocked by a potent inhibitor of autophagy, 
bafilomycin A1 (BafA1). It seems evident though that the acute phase response of ferritin 
synthesis from excess cellular labile iron overrides channeling of iron as a substrate for ROS 
generation, which paradoxically is a sine qua non for ferroptosis induction. The study showed 
an increase in endogenous ferritin heavy chain 1 (FTH1) expression during ferroptosis [19]. 
Subsequently, overexpression of FTH1 enhanced its degradation after induction of ferroptosis 
by erastin in the same study. In general, it was noted that autophagy-driven ferroptosis occurs 
during the early initiation stage [19]. The function of autophagy in cell death or survival remains 
14 
 
unclear. Autophagy is in general terms a physiological  process that conserves metabolic 
mechanisms to preserve life by degrading nutrients in the lysosome during periods of stress,  
starvation and hypoxia  [49]. Ferritinophagy, akin to this, is, an autophagic degradation of 
ferritin to release iron during situations of depletion [47] and in particular during an essential 
survival process of erythropoiesis [47]. The regulation of ferroptosis and the switch to 
ferritinophagy during pathological conditions lead to cell death [50] and this could also be 
beneficial therapeutically in the pathophysiology of cancer progression.  
There has also been much debate and controversies about the physiological relevance of the 
Fenton reaction in vivo particularly during normal iron homeostasis. The rate constant for the 
Fenton reaction is reported to be considerable lower than that of the activity of catalase upon 
H2O2 interaction [51]. Moreover, a robust amalgam of glutathione, superoxide dismutase  
(SOD), catalase and peroxiredoxin protects cells from oxyradical damage. However, under 
conditions of iron loading disorders such as hemochromatosis and iron-loading anemias, such 
as thalassemia, sickle cell disease, hemolysis and myelodysplasia, excess non-transferrin bound 
iron (NTBI) may be sequestered as ferritin in the lysosomes. Ferritin is subsequently degraded 
or its iron reduced in the acidic pH of the lysosomes where the level of chelatable iron could be 
about 15 µM.  Coupled with localised low antioxidant enzymes, this situation stimulates 
oxidative stress and the release of redox-active iron [52;53] into the cytosol from ruptured 
lysosomes. Although serum ferritin iron content is low  it is released into blood circulation 
during inflammation and in autoimmune diseases may increase iron level locally and cause 
apoptosis [54;55] or possibly ferroptosis, the new member in an array of evolving cell death 
processes. The extracellular NTBI levels may increase intracellular LIP content, execute 
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oxyradical damage [56] and generate ROS that are features of iron overload disorders. 
Prolonged iron overload leads to the sequestration of Fe as ferritin in lysosomes and this forms 
hemosiderin which is possibly an adaptation of survival mechanism for tissue iron sequestration 
that is associated with low iron content of serum. An evidence of the role of ferroptosis, in vivo 
in iron-loading disorders was reported recently in severe iron overload Hjv-/- and Smad4Alb/Alb 
mice [57] where ferrostatin-1, a ferroptosis inhibitor attenuated liver damage in the mice. The 
study also reported that while Slc7a11-/- mice did not exhibit the phenotype of ferroptosis, 
primary hepatocytes and bone marrow-derived macrophages (BMDMs) from the mice when 
exposed to iron demonstrated increased Slc7a11 expression and the   induction of ferroptosis 
[57]. Moreover, iron overload Hfe-/-, Hjv-/-, and Smad4Alb/Alb) had increased hepatic Slc7a11 
mRNA levels compared to wild-type mice. The implications of this and the antioxidant 
compensatory mechanisms in Slc7a11-/- mice require forther investigations. 
 
 
Concluding remarks: Excessive accumulation of ROS principally due to the availability of iron 
causes lipid peroxidation that culminates in ferroptosis, a form of non-apoptotic cell death. 
Ferritinophagy contributes to Fe substrate for Fenton chemistry which in part causes 
peroxidation that culminates in ferroptosis (Figure.1). While the physiological function of 
ferroptosis is not clear, the etiology is associated with disequilibrium in redox metabolism and 
subsequent pathological disorders. The answers to a number of puzzling questions are relevant 
to our clear understanding of ferroptosis. Could non-iron sources of ROS or the depletion of 
antioxidant levels independently induce ferroptosis? Is the role of iron in ferroptosis limited 
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only to induction or are there other iron-dependent genes involved downstream during lipid 
peroxidation? Does transferrin saturation cause ferroptosis and the development of 
hepatocellular carcinoma? What are the consequences of effectors of ferroptosis that have 
pleiotropic functions in other forms of cell death processes? (See outstanding questions). 
Concluding remarks: Ferroptosis has emerged as a new form of iron and ROS-dependent cell 
death. It is induced by inhibition of cysteine uptake that reduces intracellular levels of 
glutathione (GSH) and antioxidant status of the cell. Moreover, NADPH oxidase and mutant p53 
regulate ferroptosis positively by enhancing ROS production and suppressing the expression of 
the light-chain subunit of the cystine/glutamate antiporter, SLC7A11. Transferrin as 
holotransferrin and amino acid glutamine, are also inducers of ferroptosis. Redox signaling in 
ferroptosis involves the generation of phosphatidylethanolamines (PE) by 15-lipoxygenase. 
Ferritinophagy, a process of autophagic degradation of ferritin has been associated with 
ferroptosis as supplying Fe substrate in its initiation in systemic metabolism. 
Derangement, imbalance and dysregulation that occur by genetic, pharmaceutical and 
pathological conditions [58] during ferroptosis could be confounding, complicated and complex 
(Figure 3). It is promising, however, that pharmaceutical compounds may be used to activate 
ferroptosis against cancer and other diseases, while its inhibition may be employed to 
attenuate degenerative disorders. 
 
Outstanding Questions include the following 
• Is ferroptosis a normal physiological process or is it a consequence of perturbed 
oxidative metabolism? 
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• What is the critical iron status that channels NCOA4 to either autophagy or ubiquitin 
degradation? 
• Is it a pathological process that is associated with tissue specific expression of the 
different modulating components? 
• What is the role ROS-induced lipid peroxidation in the signal cascades that lead to cell 
death by ferroptosis? 
• What are the effector molecules downstream of the induction of ferroptosis? 
• Are there other p53 target genes that could contribute to ferroptosis? 
• How can ferroptosis be employed in the therapy of pathological conditions such as 
cancer, neurodegenerative diseases, heart ischemia/reperfusion injury, acute renal failure? 
 
There is no conflict of interest. 
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Figure 1. The role of iron in ROS metabolism. Fenton reaction in which ferrous iron reacts with 
hydrogen peroxide to produce the (A) hydroxyl radical (HO•)   or (B) lipid alkoxy (RO•)   Ferric 
ion from the reaction can be reduced back to ferrous iron (a) in the presence of superoxide 
(Haber–Weiss reaction). All the enzymes involved in these reactions are iron-depenednt except 
glutathione peroxidase and peroxiredoxin. (Adapted from Dixon SJ, Stockwell BR: The role of 
iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10:9-17). 
 
 
 
Figure 2. Mechanism of ferroptosis by oxidized phosphatidylethanolamines (PE). Acyl-CoA 
synthetase long-chain family member 4 (ACSL4) catalyzes the ligation of an arachidonoyl (AA) or 
adrenoyl (AdA) to produce AA or AdA acyl Co-A derivatives. AA-PE and AdA-PE are esterified to 
PE by lysophosphatidylcholine acyltransferase 3 (LPCTA3). Subsequently, AA-PE and AdA-PE, are 
oxidised by 15-lipoxygenase (15-LOX) to generate lipid hydroperoxides, the proximate 
executors of ferroptosis. (Adapted from D'Herde K, Krysko DV: Ferroptosis: Oxidized PEs trigger 
death. Nat Chem Biol 2017; 13:4-5). 
 
 
Figure 3. Role of iron, glutathione and peroxidation in ferroptosis 
Ferroptosis occurs as a result of increased ROS levels due to elevated intracellular iron 
concentration that is possibly accentuated by ferritinophagy, deranged mitochondrial function, 
and a depletion of antioxidant GSH that could be due to disruption of cysteine transport.  
Erastin, glutamate and p53 are inhibitors of cysteine transport. Low levels GPX4 activity leads to 
increased accumulation of ROS that cause lipid peroxidation and consequently to ferroptosis 
induction. Other inhibitors of ferroptosis are DFO (Fe), BafA1, CQ (Ferritinophagy), and HSPB1 
(TfR1 recycling). Liproxstatin-1 and Ferrostatin amongst others are inhibitors of peroxidation. 
Abbreviations: TF-Fe (Transferrin loaded with iron), deferrioxamine, (DFO) bafilomycin A1 
(BafA1), and chloroquine (CQ). 
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Table 1. The main features of ferroptosis, apoptosis, necroptosis and autophagy  
Cell death FERROPTOSIS APOPTOSIS NECROPTOSIS AUTOPHAGY 
Definition Iron-mediated, 
caspase-
independent cell 
death that 
requires ROS 
and lipid 
peroxides 
A caspase mediated 
programmed cell 
death 
RIPK3-dependent 
regulated necrosis. 
Autophagosome 
and 
autolysosome 
catabolic process 
to maintain 
nutrients for 
development 
and during stress 
conditions 
 
Morphological 
features 
 
Cell 
membrane 
Normal 
spherical  cells 
Plasma membrane 
blebbing of 
spherical  cells 
Plasma 
Membrane 
rupture 
 
Normal 
membrane 
structure 
Cytoplasm Diminutive 
mitochondria 
with decreased 
crista and 
collapsed and 
ruptured 
membrane 
 
Cell shrinkage and 
loss of cytoplasmic 
protrusions 
 
Cytoplasmic and 
organelles 
swelling  
 
Lysosomal 
vacuoles 
exhibit double 
membranes 
Nucleus Normal Reduced nuclear 
size and 
pronounced 
nuclear DNA 
fragmentation and 
chromatin 
condensation 
Partial chromatin 
condensation 
Normal 
Biochemical 
features 
Inhibition of 
system Xc- 
And reduced 
GSH, inhibition 
of GPX4. 
Increased Fe, 
ROS and lipid 
peroxidation, 
mitochondrial 
membrane 
Inter-nucleosomal 
DNA fragment 
Caspase activation 
mitochondrial 
membrane potential 
dissipation 
 
 
Receptor-
interacting protein 
kinase 1 is recruited 
by RIPK3. Increased 
kinase cytotoxic 
activity, decreased 
ATP levels 
 
mixed lineage 
kinase domain-like 
Microtubule-
associated 
protein light 
chain 3-1 
conversion to 
protein light 
chain 3-11, 
catabolism of 
substrates 
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Adapted from Xie et al (2) and Yu et al (58). 
 
 
potential 
dissipation 
protein MLKL 
Core 
regulators 
VDAC2/3, Ras 
NOX,TFR1, p53 
CARS, GPX4 
SLC7A11, HSPB1 
•NRF2 
p53, Bax, Bak, Bcl- 2, 
Bcl-XL 
Other pro-apoptotic 
Bcl-2 family proteins 
 
RIP1, RIP3, MLKL ATG5 
 ATG7 
Beclin 1 
Inducers System x_ 
c inhibition 
Inhibition of GCL 
Inhibition of 
GPX4 
Extrinsic: Activation 
of TNF death 
receptors 
Recruitment of 
cytoplasmic 
adaptor proteins 
(e.g. FADD 
and TRADD) 
Loss of 
mitochondrial 
transmembrane 
potential 
Mitochondrial outer 
membrane 
permeabilization 
(MOMP) 
Release of pro-
apoptotic 
proteins into cytosol 
(e.g. 
cytochrome c) 
TNFR1 activation 
Recruitment of 
TRADD and 
RIPK1 
Upregulation of 
Atg5 and Atg6 
Non-selective 
PI3K inhibitors: 
3-ME, LY294002, 
wortmannin 
 
Selective VPS34 
inhibitors: PIK-III, 
compound 31, 
SAR 405, Vps34-
In1 
Specific ULK1 
inhibitors: 
MRT68921, 
MRT67307, SBI-
0206965 
Inhibitors Lipophilic 
antioxidants 
(e.g. Fer-1, 
vitamin E) 
Iron chelators 
(e.g. DFO, 
CPX) 
Caspase inhibitors Necrostatins (e.g. 
Nec-1) 
Necrosulfonamide 
Antioxidants 
(e.g. 
vitamin E, 
idebenone) 
PD150606, a 
calpain 
inhibitor, 
Autophagy 
inhibitors (e.g. 
3-MA, 
wortmannin) 
Immune 
features 
Pro-
inflammatory 
Mostly anti-
inflammatory 
Most often pro-
inflammatory 
Most often anti-
inflammatory 
